Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
Ruxolitinib has become a new therapeutic option for steroid refractory graft-versus-host disease (srGVHD), with a substantial remission rate. Its anti-inflammatory properties by blocking interleukin pathways have made it a novel therapeutic approach to inflammatory disease processes, such as GVHD. T...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Wiley
2020-01-01
|
| Saila: | Case Reports in Oncological Medicine |
| Sarrera elektronikoa: | http://dx.doi.org/10.1155/2020/4936846 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|